Immunovaccine Technologies Inc.

Horizon Technology Finance Corporation

Marianne Michelle Stanford

Marc Mansour

Genevieve Mary Weir

Leeladhar Sammatur

Rajkannan Rajagopalan

Neil L Berinstein

Frederic Ors

Zi-hua Jiang

Jordan David Lewicky

Lisa Diana MacDonald

The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 &#x3bc;l and induces an antibody immune response to the B-cell epitope in the human subject.

Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects

The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.

Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof

The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.

Lipid A mimics, methods of preparation, and uses thereof

The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an agent that interferes with DNA replication prior to vaccination with a survivin vaccine. Also provided are compositions for use in the methods of the invention.

Method for improving the efficacy of a survivin vaccine in the treatment of cancer

Growing community of inventors

Upper Tantallon, Canada

Marianne Michelle Stanford